Tripelennamine
| 證據等級: L5 | 預測適應症: 5 個 |
目錄
Tripelennamine: From Antihistamine to Allergic Urticaria
One-Sentence Summary
Tripelennamine (pyribenzamine) is a first-generation H1 antihistamine with no formally recorded original indication in this evidence pack. The TxGNN model predicts it may be effective for Allergic Urticaria, but this is mechanistically expected rather than novel, and is currently supported only by older, low-tier literature with no clinical trials.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (no license/indication data recorded) |
| Predicted New Indication | Allergic Urticaria |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L4 |
| US Market Status | 未上市 (Not marketed) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in structured form, but based on known pharmacology, Tripelennamine is a classic first-generation H1 antihistamine. It blocks histamine H1 receptors, thereby inhibiting histamine-driven vasodilation, increased vascular permeability, and pruritus — the core pathological pathway of allergic urticaria.
This is not a novel repurposing hypothesis in the traditional sense: H1 antihistamines have long been used for histamine-mediated urticaria, so the TxGNN prediction largely reproduces a well-established pharmacological class effect rather than identifying an unexpected new use.
The mechanism plausibly applies because allergic and cold urticaria are both mast cell/histamine-mediated conditions, directly matching the drug’s known receptor-blocking action. However, supporting evidence is limited to case reports and reviews from the 1950s, with no modern clinical trials confirming efficacy or safety in this specific context.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 15414437 | 1950 | Review | California medicine | Describes histamine’s role in tissue/anaphylactic reactions and how antihistaminic drugs block (rather than antagonize) histamine action |
| 13195608 | 1954 | Case series/Uncontrolled | Schweizerische medizinische Wochenschrift | Reports experience with a new antiallergic combination preparation (abstract unavailable) |
US Market Information
No US market license/NDA data is available; the drug is currently recorded as not marketed (未上市) with 0 licenses on file.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanistic link to allergic urticaria is pharmacologically sound but represents a well-known class effect rather than a novel repurposing opportunity, and current evidence is limited to L4-tier literature from the 1950s with no clinical trials.
To proceed, the following is needed:
- Confirmed mechanism of action (MOA) data from DrugBank (currently a Blocking/High-severity data gap)
- TFDA package insert warnings/contraindications (currently a Blocking data gap — required before any S1 safety review)
- Modern clinical evidence (trials or contemporary studies) evaluating antihistamine efficacy specifically in allergic/cold urticaria populations
- Clarification of original approved indication(s), since none are currently on record
- Route of administration and dosage form availability data, currently marked “pending”
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.